Gastrointestinal perforation associated with bevacizumab in metastatic colorectal cancer

被引：3

作者：

Fang, Kunpeng ^{[1
]}

Wang, Jie ^{[2
]}

Yuan, Jianyong ^{[3
]}

Sui, Chengjun ^{[1
]}

Zhi, Jiajun ^{[4
]}

Xia, Yong ^{[5
]}

Sun, Minmin ^{[6
]}

机构：

[1] Naval Med Univ, Affiliated Hosp 3, Eastern Hepatobiliary Surg Hosp, Dept Special Treatment 1, Shanghai, Peoples R China

[2] Naval Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Hepat Surg 2, Affiliated Hosp 3, Shanghai, Peoples R China

[3] Shanghai Univ Tradit Chinese Med, Yueyang Hosp Integrated Tradit Chinese & Western M, Hepatobiliary Pancreat Surg, Shanghai, Peoples R China

[4] Shanghai Jiao Tong Univ, Xin Hua Hosp, Sch Med, Dept Colorectal & Anal Surg, Shanghai, Peoples R China

[5] Naval Med Univ, Affiliated Hosp 3, Eastern Hepatobiliary Surg Hosp, Dept Hepat Surg 4, 225 Changhai Rd, Shanghai 200438, Peoples R China

[6] Naval Med Univ, Affiliated Hosp 3, Eastern Hepatobiliary Surg Hosp, Dept Hepat Surg 1, 225 Changhai Rd, Shanghai 200438, Peoples R China

来源：

CANCER REPORTS | 2024年 / 7卷 / 02期

关键词：

adverse reactions; bevacizumab; colorectal cancer; gastrointestinal perforation; SURVIVAL;

D O I：

10.1002/cnr2.1952

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

ObjectiveTo investigate the risk factors for gastrointestinal perforation in metastatic colorectal cancer patients receiving bevacizumab.MethodsWe retrospectively reviewed 217 patients with metastatic colorectal cancer receiving bevacizumab to investigate the risk factors for gastrointestinal perforation. Three patients occurred intestinal perforation after receiving bevacizumab. We analyzed the clinical characteristics of three patients with intestinal perforation.ResultsAll patients receiving bevacizumab. Three of 217 patients occurred intestinal perforation after receiving bevacizumab. Patient no. 1 was 70 years old, female, having history of intestinal obstruction. The patient occurred intestinal perforation and ultimately died after receiving bevacizumab. Patient no. 2 was 59 years old, female, having history of intestinal obstruction. The patient occurred intestinal perforation after receiving bevacizumab, and recovered smoothly after symptomatic treatment. Patient no. 3 was 60 years old, female, having history of intestinal obstruction. The patient occurred intestinal perforation and ultimately died after receiving bevacizumab.ConclusionsPatients with advanced colorectal cancer receiving bevacizumab are at risk of gastrointestinal perforation. The patient's age, gender and history of bowel obstruction may be associated with gastrointestinal perforation.

引用

页数：7

共 20 条

[1] Management of bevacizumab-associated bowel perforation: a case series and review of the literature [J].

Badgwell, B. D. ;

Camp, E. R. ;

Feig, B. ;

Wolff, R. A. ;

Eng, C. ;

Ellis, L. M. ;

Cormier, J. N. .

ANNALS OF ONCOLOGY, 2008, 19 (03) :577-582

[2] Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer The UNICANCER PRODIGE18 Randomized Clinical Trial [J].

Bennouna, Jaafar ;

Hiret, Sandrine ;

Bertaut, Aurelie ;

Bouche, Olivier ;

Deplanque, Gael ;

Borel, Christian ;

Francois, Eric ;

Conroy, Thierry ;

Ghiringhelli, Francois ;

des Guetz, Gaetan ;

Seitz, Jean-Francois ;

Artru, Pascal ;

Hebbar, Mohamed ;

Stanbury, Trevor ;

Denis, Marc G. ;

Adenis, Antoine ;

Borg, Christophe .

JAMA ONCOLOGY, 2019, 5 (01) :83-90

[3] Colon Cancer, Version 2.2021 [J].

Benson, Al B. ;

Venook, Alan P. ;

Al-Hawary, Mahmoud M. ;

Arain, Mustafa A. ;

Chen, Yi-Jen ;

Ciombor, Kristen K. ;

Cohen, Stacey ;

Cooper, Harry S. ;

Deming, Dustin ;

Farkas, Linda ;

Garrido-Laguna, Ignacio ;

Grem, Jean L. ;

Gunn, Andrew ;

Hecht, J. Randolph ;

Hoffe, Sarah ;

Hubbard, Joleen ;

Hunt, Steven ;

Johung, Kimberly L. ;

Kirilcuk, Natalie ;

Krishnamurthi, Smitha ;

Messersmith, Wells A. ;

Meyerhardt, Jeffrey ;

Miller, Eric D. ;

Mulcahy, Mary F. ;

Nurkin, Steven ;

Overman, Michael J. ;

Parikh, Aparna ;

Patel, Hitendra ;

Pedersen, Katrina ;

Saltz, Leonard ;

Schneider, Charles ;

Shibata, David ;

Skibber, John M. ;

Sofocleous, Constantinos T. ;

Stoffel, Elena M. ;

Stotsky-Himelfarb, Eden ;

Willett, Christopher G. ;

Gregory, Kristina M. ;

Gurski, Lisa A. .

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2021, 19 (03) :329-359

[4] Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review [J].

Biller, Leah H. ;

Schrag, Deborah .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2021, 325 (07) :669-685

[5] A multi-center randomized phase II clinical study of bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for Chinese patients with metastatic colorectal cancer [J].

Cao, Ranhua ;

Zhang, Shuai ;

Ma, Dedong ;

Hu, Likuan .

MEDICAL ONCOLOGY, 2015, 32 (01) :1-5

[6] FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study [J].

Cremolini, Chiara ;

Loupakis, Fotios ;

Antoniotti, Carlotta ;

Lupi, Cristiana ;

Sensi, Elisa ;

Lonardi, Sara ;

Mezi, Silvia ;

Tomasello, Gianluca ;

Ronzoni, Monica ;

Zaniboni, Alberto ;

Tonini, Giuseppe ;

Carlomagno, Chiara ;

Allegrini, Giacomo ;

Chiara, Silvana ;

D'Amico, Mauro ;

Granetto, Cristina ;

Cazzaniga, Marina ;

Boni, Luca ;

Fontanini, Gabriella ;

Falcone, Alfredo .

LANCET ONCOLOGY, 2015, 16 (13) :1306-1315

[7] Panitumumab-FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer [J].

Douillard, Jean-Yves ;

Oliner, Kelly S. ;

Siena, Salvatore ;

Tabernero, Josep ;

Burkes, Ronald ;

Barugel, Mario ;

Humblet, Yves ;

Bodoky, Gyorgy ;

Cunningham, David ;

Jassem, Jacek ;

Rivera, Fernando ;

Kocakova, Ilona ;

Ruff, Paul ;

Blasinska-Morawiec, Maria ;

Smakal, Martin ;

Canon, Jean Luc ;

Rother, Mark ;

Williams, Richard ;

Rong, Alan ;

Wiezorek, Jeffrey ;

Sidhu, Roger ;

Patterson, Scott D. .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (11) :1023-1034

[8] Efficacy and Safety of Bevacizumab Combined With First-Line Chemotherapy in Elderly (≥75 Years) Patients With Metastatic Colorectal Cancer: A Real-World Study [J].

Francois, Eric ;

Mineur, Laurent ;

Deplanque, Gael ;

Laplaige, Philippe ;

Smith, Denis ;

Gourgou, Sophie ;

Tanang, Alexandre ;

Ionescu-Goga, Miruna ;

Veerabudun, Kalaivani ;

Lelarge, Yoann ;

Kim, Stefano ;

Rollot, Florence .

CLINICAL COLORECTAL CANCER, 2020, 19 (03) :E100-E109

[9] Bevacizumab-induced intestinal perforation in a patient with inoperable breast cancer: A case report and review of the literature [J].

Fujii Y. ;

Hirahara N. ;

Kaji S. ;

Taniura T. ;

Hyakudomi R. ;

Yamamoto T. ;

Tajima Y. .

Journal of Medical Case Reports, 12 (1)

[10] Adverse reactions associated with immune checkpoint inhibitors and bevacizumab: A pharmacovigilance analysis [J].

Gu, Tianqi ;

Jiang, Aimin ;

Zhou, Chaozheng ;

Lin, Anqi ;

Cheng, Quan ;

Liu, Zaoqu ;

Zhang, Jian ;

Luo, Peng .

INTERNATIONAL JOURNAL OF CANCER, 2023, 152 (03) :480-495

← 1 2 →